Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kyprolis in Progressive Multiple Myeloma
NCT01792102Phase 2Unknown
- Sponsor
- ONCOtherapeutics
- Start
- Apr 2013
- Primary completion
- Dec 2018
- Countries
- 1
01
Overview
Phase 2, open-label trial of carfilzomib in multiple myeloma (MM), sponsored by ONCOtherapeutics. Primary endpoint: Maximum Tolerated Dose at 24 months. Status: unknown.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01792102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792102.